Effect of calcium dobesilate in preventing contrast-induced nephropathy in patients with diabetes and chronic kidney disease
Zhang, Hao; Guo, Shao-Hua; Xue, Zheng-Kai; Zhang, Ya-Ru; Wang, Jia-Rui; Che, Jing-Jin; Liu, Tong; Tao, Hua-Yue; Li, Guang-Ping; Rha, Seung-Woon; Ashraful-Haque, Swapnil-Zaman; Chen, Kang-Yin.
Clinics
; 76: e2942, 2021. tab, graf
Artículo
en Inglés
| LILACS | ID: biblio-1345813
OBJECTIVES:
This study assessed the protective effect of calcium dobesilate against contrast-induced nephropathy (CIN) after coronary angiography (CAG) or percutaneous coronary intervention (PCI) in patients with diabetes and chronic kidney disease (CKD).METHODS:
A total of 130 patients with diabetes and CKD estimated glomerular filtration rate 30-90 mL/min/1.73m2 were enrolled and included in the analysis. They were divided into experimental (n=65) and control groups (n=65). Patients in the experimental group were administered oral calcium dobesilate (500 mg) three times daily for 2 days before and 3 days after the procedure. The serum creatinine (SCr), cystatin C (Cys C), and neutrophil gelatinase-associated lipocalin (NGAL) levels were measured before and after the procedure.RESULTS:
The mean SCr level at 24h after the procedure was found to be significantly lower in the experimental group than in the control group (79.1±19.6 μmol/L vs. 87.0±19.3 μmol/L, p=0.023). However, the Cys C and NGAL levels were not significantly different between the two groups at all measurement time points (all p>0.05). The incidence of CIN defined by the SCr level was significantly lower in the experimental group than in the control group (3 [4.6%] vs. 13 [20.0%], p=0.017). However, the incidence of CIN defined by the Cys C level was not statistically different between the two groups (7 [10.8%] vs. 7 [10.8%], p=1.000).CONCLUSIONS:
This study revealed that calcium dobesilate has no preventive effect against CIN in patients with diabetes and CKD.
Biblioteca responsable:
BR1.1
Texto completo
Documentos relacionados